Edition:
United States

Horizon Pharma PLC (HZNP.O)

HZNP.O on Nasdaq

18.82USD
26 Sep 2016
Change (% chg)

$-0.61 (-3.14%)
Prev Close
$19.43
Open
$19.24
Day's High
$19.42
Day's Low
$18.75
Volume
1,267,835
Avg. Vol
3,895,461
52-wk High
$23.70
52-wk Low
$12.86

Latest Key Developments (Source: Significant Developments)

Horizon pharma Q2 diluted earnings per share $0.09
Monday, 8 Aug 2016 07:00am EDT 

Horizon Pharma Plc : Horizon Pharma Plc announces second-quarter 2016 financial results . Sees FY 2016 sales $1.025 billion to $1.05 billion . Q2 sales $257.4 million versus I/B/E/S view $234.9 million . Qtrly earnings per share - diluted $0.09 . Qtrly non-GAAP earnings per share - diluted $0.62 .Confirms full-year 2016 net sales guidance of $1.025 to $1.050 bln and full-year 2016 adjusted EBITDA guidance of $495 to $510 mln.  Full Article

Horizon pharma says it continues to have discussions with Express Scripts
Monday, 1 Aug 2016 09:01pm EDT 

Horizon Pharma : Continues to have discussions with express scripts and sees potential pathway to completion of potential partnership with express scripts beginning 2017 .Recognizes express scripts published formulary exclusion list, which will take effect on january 1, 2017, includes duexis and vimovo.  Full Article

Horizon pharma says it continues to have discussions with Express Scripts
Monday, 1 Aug 2016 03:56pm EDT 

Horizon Pharma : Continues to have discussions with express scripts and sees potential pathway to completion of potential partnership with express scripts beginning 2017 .Recognizes express scripts published formulary exclusion list, which will take effect on january 1, 2017, includes duexis and vimovo.  Full Article

Horizon Pharma to buy rights to interferon gamma-1b from Boehringer Ingelheim
Thursday, 19 May 2016 07:00am EDT 

Horizon Pharma Plc : Says anticipates a reduction to 2016 adjusted ebitda of approximately $10 million versus prior guidance . Also licensed u.s., european and canadian intellectual property rights for interferon gamma-1b for treatment of friedreich's ataxia . Under terms of separate agreement with undisclosed third party, co licensed u.s., european, canadian ip rights for interferon gamma-1b . Co will immediately begin investing in related manufacturing, supply chain, regulatory,commercial activities for interferon gamma-1b . To immediately begin investing in related manufacturing, supply chain, regulatory and commercial activities for interferon gamma-1b . Paid boehringer ingelheim eur5 million upon signing, will pay eur20 million upon closing for rights for interferon gamma-1b in territories outside u.s, canada, japan .To Acquire Worldwide Rights To Interferon Gamma-1B from boehringer ingelheim international gmbh.  Full Article

Horizon Pharma says settles patent litigation with Teligent
Thursday, 12 May 2016 07:00am EDT 

Horizon Pharma Plc : Horizon Pharma Plc announces settlement of Pennsaid(r) (diclofenac sodium topical solution) 2 pct w/w patent litigation with Teligent Inc. .Says granted Teligent non-exclusive right to market a generic diclofenac sodium topical 2 pct w/w solution in United States.  Full Article

Horizon Pharma reports Q1 adjusted earnings per share of $0.34
Monday, 9 May 2016 07:00am EDT 

Horizon Pharma Plc Announces First : Horizon pharma plc sees 2016 net sales $1.025 billion to $1.050 billion . Quarter 2016 financial results . Q1 adjusted earnings per share $0.34 .Q1 earnings per share view $0.30 -- Thomson Reuters I/B/E/S.  Full Article

Horizon Pharma PLC announces that health Canada determines Ravicti oral liquid is eligible for data protection
Monday, 22 Feb 2016 07:00am EST 

Horizon Pharma PLC:Announces that health Canada determines Ravicti oral liquid is eligible for data protection.Ravicti would be added to register of innovative drugs,receive data protection for 8 yrs from date of issuance of notice of compliance.  Full Article

Horizon Pharma PLC and Fox Chase Cancer Center Temple Health Initiate Phase 1 Study to Evaluate ACTIMMUNE
Monday, 14 Dec 2015 07:00am EST 

Horizon Pharma PLC:Announced that it, in collaboration with Fox Chase Cancer Center Temple Health, has initiated a Phase 1 clinical study to evaluate ACTIMMUNE (interferon gamma-1b) in combination with nivolumab in advanced solid tumors.  Full Article

Horizon Pharma PLC to acquire Crealta Holdings LLC in all cash acquisition
Friday, 11 Dec 2015 07:00am EST 

Horizon Pharma PLC:Announced it has entered a definitive agreement to acquire Crealta Holdings LLC for $510 million in cash.  Full Article

Horizon Pharma plc Receives European Commission Approval for RAVICTI Oral Liquid for the Treatment of Urea Cycle Disorders in Patients Two Months of Age and Older
Monday, 30 Nov 2015 07:00am EST 

Horizon Pharma PLC:Says European Commission (EC) has adopted a binding decision to approve RAVICTI (glycerol phenylbutyrate) Oral Liquid for use as an adjunctive therapy for chronic management of adult and pediatric patients two months of age and older with six subtypes of Urea Cycle Disorders (UCDs).  Full Article

BRIEF-Raptor Pharma says to pay Horizon Pharma termination fee of $30 mln if deal terminated

* In connection with termination of merger, Raptor will be required to pay to Horizon Pharma a termination fee of $30 million Source text for Eikon: [http://bit.ly/2celZU2] Further company coverage: